With a decoupling of healthcare expenditures compared with the US GDP over the last thirty years, I have decided to examine the role of "value" in medical care in the United States, specifically with regards to innovation. What was the last new product that you have seen in medicine that was associated with a lower direct cost? Ok, how about indirect costs? And as the market is flooded with new, but costly innovations, what do these mean with ultimately delivering value to our patients?
Come see Dr. Awdeh present a lively discussion on this topic at Ocular Surgery News, in New York City, November 19, 2010.
www.osnny.com
